EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigating dosage effects of ovulation inhibitors on oocyte maturation in assisted reproductive technology: A retrospective study among patients with normal ovarian reserve

Mika Handa, Tsuyoshi Takiuchi iD, Sumika Kawaguchi, Yasuhiro Ohara, Masakazu Doshida, Takumi Takeuchi, Hidehiko Matsubayashi iD, Tomomoto Ishikawa, Sho Komukai iD, Tetsuhisa Kitamura, Tadashi Kimura

PLOS ONE · 16.01.2025 · 20 (1) · e0317103

DOI: 10.1371/journal.pone.0317103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 16.01.2025. Verfasst von Mika Handa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Gonadotropin-Releasing Hormone, Ovarian Reserve, Ovulation Induction, Oocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaken Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The judicious selection of ovulation inhibitors in ovarian stimulation protocols is crucial for the success of assisted reproductive technology (ART). Herein, we investigate the dose-dependent effects of chlormadinone acetate (CMA) and cetrorelix, two distinct ovulation inhibitors, on oocyte maturation in patients with normal ovarian reserve, using univariable and multivariable Poisson regression analyses. Patients undergoing progestin-primed ovarian stimulation (PPOS) with CMA ( n = 299) or gonadotropin-releasing hormone antagonist (GnRH-ant) with cetrorelix ( n = 605) during their initial in vitro fertilization cycle were enrolled at our center from March 2018 to October 2020 ( N = 904). The primary and secondary outcomes were the oocyte maturation and fertilization rates, respectively. After adjusting for several covariates including age, anti-Müllerian hormone levels, total gonadotropin dose, and type of trigger, we calculated the dose-dependent adjusted relative risk (aRR) and 95% confidence interval (CI) for 1 mg of CMA or 0.25 mg of cetrorelix. In the PPOS group, the median age was 34.0 years, and the median total CMA dosage was 22 mg (interquartile range [IQR]: 18.0–32.0). In the GnRH-ant group, the median age was 35.0 years, and the median total cetrorelix dosage was 0.5 mg (IQR 0.5–0.5). The aRR of the maturation rate was 1.003 (95% CI: 0.999–1.007) with PPOS ( p = 0.194) and 1.009 (95% CI: 0.962–1.059) with GnRH-ant ( p = 0.717). The aRR of the fertilization rate was 1.002 (95% CI: 0.985–1.020) with PPOS ( p = 0.783) and 1.022 (95% CI: 0.839–1.246) with GnRH-ant ( p = 0.829). Collectively, these findings indicate that within the applied dosages, ovulation inhibitors do not significantly impact oocyte maturation or fertilization rates in patients with normal ovarian reserve. These valuable insights can be applied when designing ART protocols and may guide clinicians in optimizing infertility treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gonadotropin-Releasing HormoneOvarian ReserveOvulation InductionOocytesHormone AntagonistsReproductive Techniques, AssistedHumansFemaleAdultRetrospective StudiesFertilization in VitroPregnancyDose-Response Relationship, Drug

Substanzen

Gonadotropin-Releasing HormonecetrorelixHormone Antagonists

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Department of Clinical Genomics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Clinical Study Support Center, Wakayama Medical University Hospital, Wakayama, Wakayama, Japan.
  • Department of Reproductive Medicine, Reproduction Clinic Osaka, Osaka, Osaka, Japan.
  • Department of Reproductive Medicine, Reproduction Clinic Tokyo, Minato-Ku, Tokyo, Japan.
  • Division of Biomedical Statistics, Department of Integrated Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

ORCID-Profile: Tsuyoshi Takiuchi, Hidehiko Matsubayashi, Sho Komukai

Förderung

  • Kaken Pharmaceutical

Zitieren

APA

Handa, M., Takiuchi, T., Kawaguchi, S., Ohara, Y., Doshida, M., Takeuchi, T., Matsubayashi, H., Ishikawa, T., Komukai, S., Kitamura, T., & Kimura, T. (2025). Investigating dosage effects of ovulation inhibitors on oocyte maturation in assisted reproductive technology: A retrospective study among patients with normal ovarian reserve. PLOS ONE, 20(1), e0317103. https://doi.org/10.1371/journal.pone.0317103

Vancouver

Handa M, Takiuchi T, Kawaguchi S, Ohara Y, Doshida M, Takeuchi T, et al. Investigating dosage effects of ovulation inhibitors on oocyte maturation in assisted reproductive technology: A retrospective study among patients with normal ovarian reserve. PLOS ONE. 2025;20(1):e0317103. doi:10.1371/journal.pone.0317103

BibTeX
@article{Handa2025,
  author = {Handa, Mika and Takiuchi, Tsuyoshi and Kawaguchi, Sumika and Ohara, Yasuhiro and Doshida, Masakazu and Takeuchi, Takumi and Matsubayashi, Hidehiko and Ishikawa, Tomomoto and Komukai, Sho and Kitamura, Tetsuhisa and Kimura, Tadashi},
  title = {Investigating dosage effects of ovulation inhibitors on oocyte maturation in assisted reproductive technology: A retrospective study among patients with normal ovarian reserve},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {1},
  pages = {e0317103},
  doi = {10.1371/journal.pone.0317103}
}
Kostenlos starten →